Rose Jean-Mary

FDA investigator

Appears on 15 documents from 2019 to 2025, mostly at sites in New Jersey. Most often cites responsibilities of quality control unit (21 CFR 211.22).

15
Documents on file
5.1
Observations per 483
2019
First seen
2025
Most recent

What they cite most

From 77 observations

Activity by year

2019: 1, 2020: 1, 2021: 1, 2022: 4, 2023: 1, 2024: 4, 2025: 3

Where

New Jersey 13 · India 1 · South Carolina 1

Often inspects with

Jenny Sung· Guerlain Ulysse· Suchan Kim

Is Rose Jean-Mary coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

15 documents, newest first
FirmOpen
483 Nephron SC Inc.Aug 22, 2025 · West Columbia, South Carolina
483 Hikma Injectables USA IncAug 8, 2025 · Dayton, New Jersey
483 ENGLEWOOD LAB, INC.Apr 23, 2025 · TOTOWA, New Jersey
483 Vils Pharma Coating, LLCNov 21, 2024 · Edison, New Jersey
483 Salvona Technologies, LLCOct 18, 2024 · Hamilton, New Jersey
483 Amneal Complex Products Research LLCMay 17, 2024 · Bridgewater, New Jersey
483 Imprimis NJOF, LLCApr 3, 2024 · Ledgewood, New Jersey

About this profile

What does Rose Jean-Mary inspect?

Rose Jean-Mary appears on 15 documents on file covering 14 sites, mostly in New Jersey.

What do they cite most often?

21 CFR 211.22 (responsibilities of quality control unit), followed by 21 CFR 211.67 and 21 CFR 211.68.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Rose Jean-Mary is dated Aug 22, 2025.